Biohaven Pharmaceutical: RBC’s $62 Target and Growth
RBC Capital Markets initiates coverage on Biohaven Pharmaceutical, assigning an outperform rating with a $62 price target. The firm praises ...
- Latest
- Trending
RBC Capital Markets initiates coverage on Biohaven Pharmaceutical, assigning an outperform rating with a $62 price target. The firm praises ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.